Introduction
An adequate balance in the growth hormone system appears to be needed for the maintenance of normal heart structure and function in adults. Under-as well as over-secretion is associated with increased risk of cardiovascular disease and premature mortality [1, 2] . Growth hormone deficiency is associated with reduced cardiac output and working capacity, an unfavourable lipid profile and increased risk for ischaemic heart disease [3] [4] [5] . In acromegaly the prevalence of cardiac hypertrophy, ventricular arrhythmias, hypertension, heart failure and coronary artery disease is increased [6] [7] . Correction of hormone levels improves heart function and prognosis in these conditions [8] [9] [10] [11] [12] [13] [14] [15] . In severe chronic heart failure the sensitivity to growth hormone is impaired. These patients typically have high levels of growth hormone [16] , associated with low levels of insulin-like growth factor-1 (IGF-1) which is secreted in response to growth hormone and mediate most of the effects of growth hormone [17] . A similar resistance is seen in malnutrition and severe chronic diseases of other causes [18] [19] [20] . Recent studies indicate that patients with advanced heart failure due to idiopathic dilated cardiomyopathy may benefit from treatment with growth hormone in pharmacological doses that might overcome this resistance [21] . Animal studies have shown beneficial effects of growth hormone treatment after acute myocardial infarction produced by coronary ligation [22] [23] [24] [25] [26] [27] [28] [29] . Less ventricular remodelling, aneurysm formation and heart failure have been found as well as improved survival.
Reports on the growth hormone system in ischaemic heart disease and acute myocardial infarction in humans are still lacking. Our aim was to investigate endogenous growth hormone/insulin-like growth factor-1 activity in consecutive patients with acute myocardial infarction in relation to heart function.
Methods

Study population
Fifty-two patients presenting with chest pain and subsequently proven acute myocardial infarction were studied in the coronary care unit at our hospital. The recruitment of patients was strictly consecutive. Accordingly, no exclusions were made due to age, delay since pain onset, prior heart function or any other criteria. Characteristics of the study population are shown in Table 1 . The mean age of the study group was 69 13 years, 19 were females. Less than half of the patients (n=24) suffered Q wave infarctions. Less than onethird of the patients were treated with thrombolysis. None were in cardiogenic shock and no inotropics were used. No patients had primary angioplasty. Two patients underwent percutaneous transluminal coronary angioplasty (PTCA) within the first 5 days.
Median delay from pain onset until first sample was 7 h 20 min. All patients arrived at the hospital within 48 h after pain onset and only four patients later than within 24 h. In the analysis, the time from the onset of chest pain was used. Follow-up examinations were performed 6 and 12 weeks after the infarction. Three patients died within the first month, five within the first year and 12 within 2 years, of whom eight died from cardiovascular disease.
Biochemical assays
Blood samples were drawn on admittance and four times daily (at 06.00, 12.00, 18.00 and 00.00 h) for 2 days, then every morning at 06.00 h for another 3 days and at follow-up visits 6 and 12 weeks later. The samples were centrifuged for 10 min and serum was aspirated and frozen at 20 C directly in the coronary care unit.
Serum growth hormone levels was analysed by IRMA assay in a DELFIA system supplied by Wallac Oy, Turku, Finland. All growth hormone values presented here are mean values, either of the whole group or of subgroups. These, in turn are derived from individual mean values of samples obtained within a specified time interval from pain onset. Thus, the mean value during the first 5 days is based on the mean value of 12 samples for each patient. The reason for collecting and treating data in this way is that interpretation of individual growth hormone values is extremely difficult since growth hormone is secreted in discrete secretory bursts with relative secretory quiescence in between. Short serum half-life (approximately 20 min) makes levels vary widely under normal conditions [30, 31] . For a single sample any value between the undetectable and 5·6 g . l 1 is regarded as normal. In our study levels varied between 0·01 g . l 1 and 11·2 g . l 1 . The values presented thus consist of samples obtained during peaks as well as during troughs and cannot be compared with values from other patient groups with different sampling routines from ours. Ideally, sampling should have been done in 5 min intervals during the study period. It was, however, not considered ethical to perform this in patients with acute myocardial infarction.
Determination of IGF-1 was made from morning samples, after extraction with acidified ethanol, by radioimmunoassay using a commercial kit obtained from Nichols Institute, San Juan Capistrano, California, U.S.A. Infarction size was estimated by levels of troponin T registered 18 6 h after admission, by peak levels of creatine kinase-MB (mass) from samples collected every 6 h as well as by the area under the curve of creatine kinase-MB of samples obtained every 6 h until values had returned to normal. In the analysis of cortisol and glucose, fasting morning samples were obtained once daily. 
Echocardiography
On the third day echocardiography was performed. Systolic left ventricular function was estimated by the ejection fraction calculated by the Teichholz equation [32] and by the mean displacement of the atrioventricular plane [33] . Cardiac output and left ventricular muscle mass index were calculated using systolic and diastolic volumes obtained by parasternal M mode recordings. The examination was repeated after 6 weeks by the same observer.
Statistical methods
In the statistical analysis, each sample is treated as belonging to a certain time interval, counting from onset of symptoms. When more than one sample was acquired during the same period, mean values are used. As a consequence of differences in delay between pain onset and the first sample being taken, the number of patients that presented for early time intervals, before all patients had arrived, is incomplete. (The number of patients in these intervals are: 22 patients in the 0-6 h period, 34 patients in the 6-12 h period, 37 patients in the 12-18 h period and 43 patients in the 18-24 h period.)
Results are presented as means and standard deviations in characterization of all patients and as standard error of the mean (SEM) when values from different groups or different occasions are compared. Only nonparametric tests were used due to the size of the study population and due to skewed distribution of data, particularly of growth hormone concentrations. The Mann-Whitney U-test, Wilcoxon signed rank test and Spearman rank correlation were used for continuous data and the chi-squared tests for discrete variables. A two-tailed P value <0·05 was regarded as significant.
Results
Growth hormone in acute myocardial infarction
Mean serum growth hormone concentration within the first 24 h from pain onset was 0·8 0·1 g . l 1 . It decreased successively reaching the lowest level on day three at 0·4 0·05 g . l 1 (P<0·0005) where it remained for the rest of the hospital period (Fig. 1) . The earlier samples were acquired the higher the growth hormone levels. Within the first 6 h from pain onset mean levels were 1·1 0·2 g . l 1 (n=22) versus 0·6 0·1 g . l 1 (n=43) in the period 18-24 h after pain onset (P<0·05). In the majority of patients the decline was completed within the first 24 h. At follow-up 6 and 12 weeks after the infarction median growth hormone levels remained low (0·3 g . l 1 and 0·4 g . l 1 respectively), while mean values were higher (0·8 0·2 g . l 1 and 1·0 0·2 g . l 1 , respectively) due to high levels in a minority of patients.
Insulin-like growth factor-1 in acute myocardial infarction
The mean IGF-1 level within the first 24 h was 148 9 g . l 1 (n=47) and on the second day 165 11 g . l 1 (Fig. 1 ). This increase was not significant. From then on, mean values for all patients tended to decrease during the hospital period, although the changes were not significant day by day. However, the mean level within the first 48 h was significantly higher than during the fourth and fifth day (158 11 g . l 1 vs 138 10 g . l 1 , P<0·05). Significant change was also found between mean values during the first 24 h and the mean of lowest individual values (121 8 g . l 1 , P<0·0001), which occurred on the fourth or fifth day in the majority of patients. Six weeks after infarction IGF-1 levels had returned to the initial level on day one.
Mean IGF-1 levels did not at any time differ from levels found in another study, which included a normal healthy population [34] . On the first day mean values were 0·06 standard deviations above, and on the fifth day 0·31 standard deviations below, the age corrected mean for a normal healthy population.
Myocardial damage and inflammation
Growth hormone levels during the first 24 h correlated with the severity of myocardial damage, as estimated by 
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troponin T levels in samples obtained 18 6 h after pain onset (r=0·36, P<0·05). Correlation was also found with peak levels of creatine kinase-MB (r=0·30, P<0·05), and with the area under the curve of creatine kinase-MB (r=0·30, P<0·05). Patients with an area under the curve above the mean still had higher growth hormone levels on days 3-5 when the acute elevation had subsided (0·6 0·1 g . l 1 vs 0·3 0·05 g . l 1 , P<0·005). No significant differences were found in mean growth hormone levels during the first 5 days whether thrombolysis was given or not, or whether the infarction resulted in a new Q wave on the ECG or not. No correlation was found between cardiac enzymes and IGF-1 levels during the study period.
Serum levels of cortisol and C-reactive protein, substances related to stress and inflammation, increased during the days following infarction. Cortisol levels were maximal on day one and C-reactive protein reached maximal level on the third day (Fig. 2) . Correlations were found between troponin T levels and peak levels of C-reactive protein (r=0·58, P<0·0005) as well as between peak levels of creatine kinase-MB and Creactive protein (r=0·31, P<0·05). No correlations of cortisol with cardiac enzymes were found. Mean levels of C-reactive protein and growth hormone correlated during the first 5 days (r=0·31, P<0·05). Those with growth hormone levels above the median during the first 5 days had a mean serum level of C-reactive protein that was 83 13 mg . l 1 compared with 35 7 mg . l 1 in patients with lower growth hormone levels (P<0·005). No correlations were found between C-reactive protein and IGF-1. Mean levels of cortisol during the first 5 days correlated positively with growth hormone (r=0·37, P<0·01) levels but not with IGF-1 levels during the same time.
Metabolism
Eleven patients with previously diagnosed non-insulindependent diabetes mellitus had mean serum growth hormone levels of 0·4 0·1 g . l 1 during the first 5 days compared with 0·7 0·1 g . l 1 (P<0·05) in non-diabetic patients. This association was strongest in early samples. Thus, in samples within the first 12 h nine patients with diabetes had a mean growth hormone level of 0·3 0·1 g . l 1 compared with 1·1 0·2 g . l 1 in 16 non-diabetic patients (P=0·0005). Levels of IGF-1 tended to be lower in diabetics at all times but differences were not significant. Negative correlation was found between fasting morning glucose levels and growth hormone during the first 5 days (r= 0·35, P<0·02). Glucose levels tended also to correlate negatively with IGF-1 but without statistical significance (r= 0·24, P=0·09).
Daily records of whether patients were eating normally, less than normally or fasting during the hospital period did not correlate with growth hormone or IGF-1 levels. Correlation between body mass index and mean growth hormone levels was found in both men and women (r= 0·35, P<0·05) but not between body mass index and IGF-1 levels. Mean triglyceride levels in samples obtained once daily during the first 5 days correlated negatively with growth hormone (r= 0·36, P<0·01) but not with IGF-1. No relation was found with cholesterol for either growth hormone or IGF-1. 
P<0·005). (b) Mean serum levels of growth hormone (GH) after infarction. Patients with CRP levels higher than the mean value ( ) during the first 5 days (48 mg . l 1 ) had higher GH levels during this period (0·9 0·1 g . l 1 vs 0·5 0·1 g . l 1 , P<0·05), than patients with CRP levels less than the mean value ( ).
A negative correlation was found on days 3-5 between the biologically active hormone T3, an important regulator of metabolic rate, and growth hormone levels (r= 0·49, P<0·001). No significant correlation was found between levels of T3 and IGF-1.
Heart failure and ventricular dysfunction
Echocardiography on the third day showed negative correlation between left ventricular ejection fraction and growth hormone levels during days 3-5 (r= 0·45, P<0·005). Correlation was also found between mean atrioventricular displacement and growth hormone levels during these days (r= 0·35, P<0·05) and between cardiac output and growth hormone levels (r= 0·46, P<0·005). Levels of IGF-1 and mean atrioventricular displacement correlated positively (r=0·36, P<0·05) whereas its correlation with left ventricular ejection fraction or cardiac output did not reach statistical significance. However, IGF-1 levels correlated with left ventricular ejection fraction using samples from the whole study period (r=0·29, P<0·05). Patients with IGF-1 levels above median had a better left ventricular ejection fraction than others (50 2% vs 43 3%, P<0·05, Fig. 3) .
On re-examination 6 weeks later, measures of left ventricular systolic function had improved slightly: for left ventricular ejection fraction from 47% to 50% (ns), for atrioventricular plane displacement from 9·0 mm to 10·0 mm (P<0·005) and for cardiac output from 4·6 l . min 1 to 4·8 l . min 1 (ns). These changes did not correlate with growth hormone or IGF-1 levels on any occasion.
Mean levels IGF-1 on the first day correlated inversely with diastolic left ventricular diameter (r= 0·34, P<0·05) and with left ventricular muscle mass index (r= 0·32, P<0·05). No relation was found with growth hormone levels. Patients who were prescribed diuretics on the indication of heart failure at discharge (n=30) had higher growth hormone concentrations (0·5 0·1 g . l 1 vs 0·2 0·04 g . l 1 , P<0·001) than the others during days 3-5. Their IGF-1 levels did not differ significantly.
Mortality
Two years after infarction, twelve patients had died. Eight of these died of cardiovascular causes (five from acute myocardial infarction, two from heart failure and one from stroke preceded by myocardial infarction). These eight patients had significantly higher growth hormone levels and lower IGF-1 levels at all times compared with the survivors (Fig. 4 ). The mean growth hormone level during the whole study period (14 samples from each patient) was 1·1 0·2 g . l 1 in the deceased compared with 0·6 0·1 g . l 1 in survivors (P<0·005). Their mean IGF-1 level during the study period (seven samples from each patient) was 99 14 g . l 1 vs 160 10 g . l 1 (P<0·01). The difference in IGF-1 levels remained significant after correction for age. Characteristics of the deceased are compared with the survivors in Table 2 . Both groups had normal body mass index but the survivors showed 
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significantly higher body mass index and IGF-1 levels in association with lower growth hormone levels than those who died.
Discussion
A successive decline of mean serum concentrations of growth hormone was found in patients with acute myocardial infarction after admittance to hospital. The decline was almost completed within the first 18 h. In blood samples obtained within 6 h from pain onset, the mean concentration was approximately three times higher than during the following days. This may be due to a secretory surge occurring soon after the onset of infarction, before patients had reached the hospital. The larger the myocardial damage, the higher were the growth hormone levels and the slower the decline. Patients who died during follow-up showed significantly higher growth hormone levels during the hospital period than the survivors. These acute increases of growth hormone levels are analogous with earlier findings in catabolic patients with severe chronic illnesses from other causes.
During the hospital period, IGF-1 levels declined successively, although less than growth hormone levels. In contrast to intensive care patients with prolonged illness from other causes, mean levels of IGF-1 were normal in the majority of patients with acute myocardial infarction during the whole 5-day hospital period [16] [17] [18] . Although mean IGF-1 levels declined while mean growth hormone levels increased during the acute phase, these changes were small in the majority of patients. Thus, outright growth hormone insensitivity is not a feature of the acute phase of uncomplicated acute myocardial infarction. Development of growth hormone resistance, as in starvation and severe chronic heart failure, takes longer to develop than during the acute illness in myocardial infarction. However, eight patients who died from cardiovascular disease within the following 2 years differed from survivors in having significantly lower IGF-1 and higher growth hormone levels in a pattern clearly indicating insensitivity to growth hormone (Fig. 4) .
Growth hormone levels were higher in patients with impaired left ventricular function than in others; the peak was higher and levels remained higher during the study period. There was a relatively weak association between low IGF-1 levels and poor heart function. The longer elimination time of IGF-1, depending on extensive binding to carrier proteins, makes changes in levels slower than in the case of growth hormone [35] . On echocardiographical re-examination during convalescence 6 weeks later, only slight and barely significant improvement of cardiac function was detected. These differences were too small for the detection of any influences from endogenous hormone levels. If such influences exist, a larger study population with more severely ill patients is required to confirm their presence.
The acute changes in the growth hormone concentration appeared to be linked to the degree of the inflammatory reaction and stress elicited by the infarction. Hence, the higher the levels of C-reactive protein, the higher were the levels of growth hormone. Cortisol, which under normal conditions is an antagonist of growth hormone release, correlated positively with growth hormone, indicating the presence of common stimuli associated with infarction [36, 37] . Glucose correlated negatively with growth hormone in a normal fashion even under such extreme conditions as an acute myocardial infarction.
In our opinion, the focus in future clinical studies on the relationship between cardiac function and the growth hormone concentration should be on IGF-1 rather than on the rapidly changing growth hormone. The levels of IGF-1 are more relevant for the evaluation of the tone in the growth hormone direction and are easier to monitor, although it might not be a sensitive instrument for detection of rapid, acute events. Low levels of IGF-1 after myocardial infarction, as found in those who died, might be an indicator of a poor prognosis. Further studies are needed to clarify whether the increased secretion of growth hormone during acute myocardial infarction is part of an adaptive response to protect the heart. As has previously been shown, exogenous administration of growth hormone increases myocardial contractility and biomechanical efficiency, reduces afterload and wall tension and thereby reduces myocardial oxygen demand [21] . Experiments on animal models have shown less ventricular remodelling, aneurysm formation and apoptosis of cardiomyocytes as well as improved survival [22] [23] [24] [25] [26] [27] [28] [29] . It remains to be seen whether patients with severe heart failure after myocardial infarction and signs of growth hormone resistance can benefit from treatment with recombinant growth hormone in order to restore the IGF-1 levels.
Conclusion
Growth hormone levels are increased during acute myocardial infarction, particularly in patients with large infarctions, impaired left ventricular function and intense inflammatory response. Patients who died during follow-up had higher levels of growth hormone and lower levels of IGF-1, indicating resistance to growth hormone. Endogenous levels of growth hormone or IGF-1 did not correlate with the degree of improvement in left ventricular function at 6 weeks, although the overall changes were very small, making it difficult to detect any influence, if such an influence exist.
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